Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Initiation of REVEAL pediatric trial in the U.S.broadens the clinical evaluation of TSHA-102 to female patients 5-8 years old with stage three Ret...

Related Keywords

Canada ,United Kingdom ,Dallas ,Texas ,United States ,University Medical Center ,Chicago ,Illinois ,Elizabeth Berry Kravis ,Sukumar Nagendran ,Carolyn Hawley ,Hayleigh Collins ,Company Contact ,Nasdaq ,Exchange Commission ,Taysha Gene Therapies Inc ,Head Of Corporate Communications ,Canale Communications ,European Commission ,Regulatory Agency ,Ut Southwestern Gene Therapy Program ,United Statesbroadens ,Gene Therapies ,Clinical Trial Application ,Responsive Auto Regulatory Element ,Medical Center ,Principal Investigator Elizabeth Berry Kravis ,Cell Biology ,Principal Investigator ,Maximum Administered Dose ,Maximum Tolerated Dose ,Fast Track ,Orphan Drug ,Rare Pediatric Disease ,Gene Therapy ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Corporate Communications ,